Application of CRISPR-Cas 9 system in cancer therapy
DOI:
https://doi.org/10.54097/s50r4154Keywords:
CRISPR-Cas9; cancer; gene therapy; immunotherapy; CAR T-cell therapy.Abstract
There are several gene editing technologies under the background of that time, such as ZFN and TALEN which are hard to use and have high cost. On the contrary, the efficiency and accuracy of CRISPR-Cas system has attracted the attention of scientists. CRISPR is a Short palindromic repeat sequence, and it is widespread in many prokaryotes. The first CRISPR was cloned in E. coli by scientists in 1987, and several other sequences were subsequently cloned. The Cas is a nuclease, then two of them cooperate to become the CRISPR-Cas system. It is not only an acquired immune defense mechanism of prokaryotes against virus, but also a tool for gene editing. As an emerging gene editing technology in recent years, CRISPR-Cas9 technology has been widely applied to the treatment of a variety of diseases. This review focused on the application of this technology in cancer. This review systematically introduced the working principle and immune mechanism of CRISPR-Cas9 and compared CRISPR-Cas9 technology with two previous generations of gene-editing technology, current application of CRISPR-Cas9 in cancer treatment, elaborating it with relevant examples, and finally pointed out the challenges of CRISPR-Cas9 in cancer treatment, looking forward to the development of this technology in the future. The purpose of the paper is to introduce and popularize CRISPR-Cas9 technology, and to provide a direction for future cancer treatment.
Downloads
References
Hausman, Daniel M. "What Is Cancer?" Perspectives in Biology and Medicine, vol. 62 no. 4, 2019, p. 778-784.
Roy, P S, and B J Saikia. “Cancer and cure: A critical analysis.” Indian journal of cancer vol. 53,3(2016): 441-442.
Ma, Yuanwu et al. “Genome modification by CRISPR/Cas9.” The FEBS journal vol.281,23(2014):5186-93.
Jiang, Fuguo, and Jennifer A Doudna. “CRISPR-Cas9 Structures and Mechanisms.” Annual review of biophysics vol. 46 (2017): 505-529.
Hryhorowicz, Magdalena et al. “CRISPR/Cas9 Immune System as a Tool for Genome Engineering.”Archivum immunologiae et therapiae experimentlis vol. 65,3 (2017): 233-240.
Amitai, Gil, and Rotem Sorek. “CRISPR-Cas adaptation: insights into the mechanism of action.” Nature reviews. Microbiology vol. 14, 2 (2016): 67-76.
Gupta, Rajat M, and Kiran Musunuru. “Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9.” The Journal of clinical investigation vol. 124,10 (2014): 4154-61.
Bhat, Ajaz A et al. “Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.” Journal of translational medicine vol. 20,1 534. 18 Nov. 2022,
Morris, Luc G T, and Timothy A Chan. “Therapeutic targeting of tumor suppressor genes.” Cancer vol. 121,9 (2015): 1357-68.
Malina, Abba et al. “Repurposing CRISPR/Cas9 for in situ functional assays.” Genes & development vol. 27,23 (2013): 2602-14.
Moses, Colette et al. “Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System.” Molecular therapy. Nucleic acids vol. 14 (2019): 287-300.
Valletta, Simona et al. “ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.” Oncotarget vol. 6,42 (2015): 44061-71.
Garmendia, Irati et al. “YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.” American journal of respiratory and critical care medicine vol. 200,7 (2019): 888-899.
Koo, Taeyoung et al. “Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.” Nucleic acids research vol. 45,13 (2017): 7897-7908.
Zhen, Shuai, and Xu Li. “Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.” Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology vol. 44,6 (2017): 2455-2466.
Dastjerd, Niloufar Tavakoli et al. “Gene therapy: A promising approach for breast cancer treatment.” Cell biochemistry and function vol. 40,1 (2022): 28-48.
Razeghian, Ehsan et al. “A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.” Stem cell research & therapy vol. 12,1 (2021)428. 28.
Dimitri, Alexander et al. “Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.” Molecular cancer vol. 21, 1(2022): 78. 18.
Eyquem, Justin et al. “Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.” Nature vol. 543,7643 (2017): 113-117.
Lu, You et al. “Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.” Nature medicine vol. 26,5 (2020): 732-740.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
